Sherlock Biosciences
Sherlock Biosciences, located in Watertown, MA, focuses on democratizing and decentralizing testing through CRISPR and synthetic biology platforms to personalize healthcare and impact global health.
Services
Sherlock Biosciences is dedicated to democratizing and decentralizing testing in healthcare. Their services focus on providing rapid, accurate, and affordable diagnostic tools. Sherlock Biosciences offers CRISPR-based diagnostics, along with synthetic biology-based solutions. They cater to research, clinical, and at-home settings, ensuring accessibility and personalization of healthcare. Furthermore, their AI-driven innovation accelerates molecular diagnostic design and development.
Products
Sherlock Biosciences' product portfolio includes the CRISPR-based SHERLOCK™ platform and the synthetic biology-based INSPECTR™ platform. The SHERLOCK™ platform is designed for the detection of DNA and RNA sequences in various organisms or pathogens, and is adaptable for multiple throughput systems. The INSPECTR™ platform uses freeze-dried synthetic gene networks for molecular diagnostics. Additionally, their ambient temperature amplification technology enables instrument-free diagnostics delivering PCR-quality results.
Technology and Innovation
Sherlock Biosciences leverages proprietary platforms for DNA and RNA detection powered by CRISPR and synthetic biology. They have over 65 patents and more than 20 publications. Their AI-driven innovation engine advances molecular diagnostic design and enables novel Cas enzyme discovery. The company’s AI tools accelerate assay design, making development of molecular diagnostic products more predictable and rapid.
Collaborations and Acquisitions
Sherlock Biosciences collaborates with Tolo Biotech to advance CRISPR-based diagnostics. They also acquired Sense Biodetection to further CRISPR-based diagnostic solutions for consumers. Additionally, Sherlock Biosciences licensed ambient nucleic acid amplification technology from Harvard's Wyss Institute. Their 221b Foundation partners with global health institutions to develop and distribute diagnostic solutions for underserved populations.
Awards and Recognition
In 2022, Sherlock Biosciences was named the PM360 Trailblazer Company of the Year for Medical Device/Diagnostics. They have received significant funding amounting to $111 million to date, supporting their innovation in the diagnostics field. Their Sherlock™ CRISPR-based SARS-CoV-2 kit was the first FDA-authorized CRISPR-based EUA diagnostic test, marking a critical milestone in CRISPR diagnostics.